In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pierre Fabre Group

www.pierre-fabre.com

Latest From Pierre Fabre Group

Boehringer Ingelheim Snaps Up Lupin's MEK Inhibitor For Difficult-To-Treat Cancers

Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.

Deals Cancer

New Keytruda Combo Wins Funding In England For NSCLC

MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.

United Kingdom Reimbursement

Alvogen's Lotus Debuts European Vinorelbine

Alvogen is claiming the first European launch of a rival to Pierre Fabre’s Navelbine in Europe, through the generics firm’s Lotus Pharmaceuticals subsidiary.

Generic Drugs Launches

Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.

M & A Business Strategies
See All

Company Information

UsernamePublicRestriction

Register